BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strik AS, Berends SE, Mathôt RA, D'Haens GR, Löwenberg M. Golimumab for moderate to severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2017;11:401-6. [PMID: 28276288 DOI: 10.1080/17474124.2017.1303376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Stefanovic S, Detrez I, Compernolle G, Brouwers E, Sever N, Stabuc B, Smrekar N, Kurent T, Novak G, Kozelj M, Ferrante M, Gils A, Drobne D. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Eur J Gastroenterol Hepatol 2021;33:54-61. [PMID: 32804854 DOI: 10.1097/MEG.0000000000001843] [Reference Citation Analysis]
2 Visuri I, Eriksson C, Olén O, Cao Y, Mårdberg E, Grip O, Gustavsson A, Hjortswang H, Karling P, Montgomery S, Myrelid P, Ludvigsson JF, Halfvarson J; SWIBREG study group. Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Aliment Pharmacol Ther 2021;54:931-43. [PMID: 34286871 DOI: 10.1111/apt.16525] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018;11:215-26. [PMID: 29844695 DOI: 10.2147/JIR.S165330] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
4 Roy A, Geetha RV, Magesh A, Vijayaraghavan R, Ravichandran V. Autoinjector - A smart device for emergency cum personal therapy. Saudi Pharm J 2021;29:1205-15. [PMID: 34703373 DOI: 10.1016/j.jsps.2021.09.004] [Reference Citation Analysis]
5 Fousekis FS, Papamichael K, Kourtis G, Albani EN, Orfanidou A, Saridi M, Katsanos KH, Christodoulou DK. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease. Ann Gastroenterol 2022;35:1-7. [PMID: 34987282 DOI: 10.20524/aog.2021.0682] [Reference Citation Analysis]